Myricetin (Synonyms: 杨梅素; Cannabiscetin)

目录号: HY-15097 纯度: 98.42%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Myricetin是常见的植物来源的类黄酮，具有广泛的活性，包括强抗氧化，抗癌，抗糖尿病和抗炎活性。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Myricetin Chemical Structure

CAS No. : 529-44-2

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥397	In-stock
25 mg	￥361	In-stock
50 mg	￥500	In-stock
100 mg	￥700	In-stock
200 mg	￥1000	In-stock
500 mg	￥1900	In-stock
1 g		询价
5 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Myricetin:

MCE 顾客使用本产品发表的 13 篇科研文献

: Myricetin purchased from MCE. Usage Cited in: Int Immunopharmacol. 2019 Oct;75:105742. [Abstract]; Myricetin suppresses the generation of inflammatory mediators in IL-1β induced human chondrocytes. The protein expression of iNOS and COX-2 in chondrocytes is determined by western blots.

Myricetin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 PI3K 亚型特异性产品:

查看所有亚型

PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Myricetin is a common plant-derived flavonoid with a wide range of activities including strong anti-oxidant, anticancer, antidiabetic and anti-inflammatory activities.

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	IC₅₀	14.8 mg/mL Compound: 23	Cytotoxicity against human A549 cells after 3 days by SRB assay Cytotoxicity against human A549 cells after 3 days by SRB assay	[PMID: 15568778]
BV-2	IC₅₀	> 100 μM Compound: 2	Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction	[PMID: 27623545]
CWR22R	IC₅₀	13.1 μM Compound: 13	Antiproliferative activity against human 22Rv1 cells incubated up to 144 hrs by Coulter particle count and size analyzer Antiproliferative activity against human 22Rv1 cells incubated up to 144 hrs by Coulter particle count and size analyzer	[PMID: 22789812]
H9	EC₅₀	35 μM Compound: 16	Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay	[PMID: 8158164]
H9	IC₅₀	69 μM Compound: 16	Cytotoxicity against human H9 cells after 3 days Cytotoxicity against human H9 cells after 3 days	[PMID: 8158164]
HCT-116	IC₅₀	> 20 μM Compound: Myricetin	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 32886510]
HCT-116	IC₅₀	23 μM Compound: 3	Growth inhibition of human HCT116 cells overexpressing PI3Kalpha after 48 hrs by MTT assay Growth inhibition of human HCT116 cells overexpressing PI3Kalpha after 48 hrs by MTT assay	[PMID: 22212721]
HCT-116	IC₅₀	24 μM Compound: 3	Growth inhibition of human HCT116 cells after 48 hrs by MTT assay Growth inhibition of human HCT116 cells after 48 hrs by MTT assay	[PMID: 22212721]
HCT-116	IC₅₀	28.2 μM Compound: 206b	Cytotoxicity against human HCT116 cells assessed as reduction in cell growth by WST-1 assay Cytotoxicity against human HCT116 cells assessed as reduction in cell growth by WST-1 assay	[PMID: 30917303]
HCT-116	IC₅₀	4.1 μM Compound: 3	Growth inhibition of human HCT116 cells overexpressing PI3Kalpha H1047R mutant after 48 hrs by MTT assay Growth inhibition of human HCT116 cells overexpressing PI3Kalpha H1047R mutant after 48 hrs by MTT assay	[PMID: 22212721]
HEK293	IC₅₀	> 10 μM Compound: 23	Inhibition of human TRPC5 expressed in HEK293 cells assessed as reduction in gadolinium-induced calcium entry after 30 mins by fluo-4 dye based fluorescence assay Inhibition of human TRPC5 expressed in HEK293 cells assessed as reduction in gadolinium-induced calcium entry after 30 mins by fluo-4 dye based fluorescence assay	[PMID: 30943030]
HepG2	IC₅₀	> 20 μM Compound: Myricetin	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 32886510]
HK-2	IC₅₀	> 20 μM Compound: Myricetin	Cytotoxicity against human HK2 cells assessed as cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HK2 cells assessed as cell viability incubated for 24 hrs by MTT assay	[PMID: 32886510]
HT-29	IC₅₀	> 20 μM Compound: Myricetin	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 32886510]
HT-29	IC₅₀	2.12 μM Compound: Myricetin	Desensitization of GPR35 receptor in human HT-29 cells assessed as inhibition of zaprinast-induced dynamic mass redistribution after 10 mins Desensitization of GPR35 receptor in human HT-29 cells assessed as inhibition of zaprinast-induced dynamic mass redistribution after 10 mins	[PMID: 24900447]
HT-29	EC₅₀	3.02 μM Compound: Myricetin	Agonist activity at GPR35 receptor in human HT-29 cells after 10 mins by dynamic mass redistribution assay Agonist activity at GPR35 receptor in human HT-29 cells after 10 mins by dynamic mass redistribution assay	[PMID: 24900447]
Huh-7	CC₅₀	> 50 μM Compound: 28	Cytotoxicity against human Huh7.5.1 cells by MTT assay Cytotoxicity against human Huh7.5.1 cells by MTT assay	[PMID: 22445328]
Huh-7	EC₅₀	46.9 μM Compound: 28	Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay	[PMID: 22445328]
Jurkat	IC₅₀	10 μM Compound: Myricetin	Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method	[PMID: 30776692]
Jurkat	IC₅₀	12 μM Compound: Myricetin	Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method	[PMID: 30776692]
L02	IC₅₀	> 20 μM Compound: Myricetin	Cytotoxicity against human L02 cells assessed as cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human L02 cells assessed as cell viability incubated for 24 hrs by MTT assay	[PMID: 32886510]
L929	EC₅₀	55 μM Compound: myricetin	Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining	[PMID: 9287415]
L929	EC₅₀	59 μM Compound: myricetin	Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay	[PMID: 9287415]
MCF7	IC₅₀	> 20 μM Compound: Myricetin	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 32886510]
MCF7	IC₅₀	4.7 mg/mL Compound: 23	Cytotoxicity against human MCF7 cells after 3 days by SRB assay Cytotoxicity against human MCF7 cells after 3 days by SRB assay	[PMID: 15568778]
MV4-11	GI₅₀	> 50 μM Compound: 7	Cytotoxicity against human MV4-11 cells harboring FLT3 mutation after 72 hrs by tetrazolium based Ez CyTox cell viability assay Cytotoxicity against human MV4-11 cells harboring FLT3 mutation after 72 hrs by tetrazolium based Ez CyTox cell viability assay	[PMID: 23411073]
Peritoneal macrophage	IC₅₀	99 μM Compound: kp22	Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method	[PMID: 27955927]
RS4-11	GI₅₀	> 50 μM Compound: 7	Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by tetrazolium based Ez CyTox cell viability assay Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by tetrazolium based Ez CyTox cell viability assay	[PMID: 23411073]
SK-BR-3	IC₅₀	> 100 μM Compound: 4	Induction of apoptosis in human SKBR3 cells assessed as PARP cleavage by Western blotting analysis Induction of apoptosis in human SKBR3 cells assessed as PARP cleavage by Western blotting analysis	[PMID: 24548207]
SK-BR-3	IC₅₀	> 100 μM Compound: 4	Inhibition of Hsp70 in human SKBR3 cells assessed as RAF1 protein degradation by Western blotting analysis Inhibition of Hsp70 in human SKBR3 cells assessed as RAF1 protein degradation by Western blotting analysis	[PMID: 24548207]
SK-BR-3	IC₅₀	> 100 μM Compound: 4	Inhibition of Hsp70 in human SKBR3 cells assessed as HER2 protein degradation by Western blotting analysis Inhibition of Hsp70 in human SKBR3 cells assessed as HER2 protein degradation by Western blotting analysis	[PMID: 24548207]
SK-BR-3	IC₅₀	13.5 μM Compound: 4	Displacement of GM-cy3B from Hsp90 in human SKBR3 cells after 24 hrs by fluorescence polarization assay Displacement of GM-cy3B from Hsp90 in human SKBR3 cells after 24 hrs by fluorescence polarization assay	[PMID: 24548207]
U2OS	EC₅₀	14.7 μM Compound: Myricetin	Agonist activity at GPR35 receptor in human U2OS cells coexpressing Gal4-VP16-TEV assessed as beta arrestin translocation after 5 hrs by beta lactamase reporter gene assay Agonist activity at GPR35 receptor in human U2OS cells coexpressing Gal4-VP16-TEV assessed as beta arrestin translocation after 5 hrs by beta lactamase reporter gene assay	[PMID: 24900447]

体外研究
(In Vitro)

Myricetin 对多种自由基和离子具有清除活性。它在超氧化物歧化酶 (SOD) 样活性测定^[1]中表现出较差的活性 (IC₅₀ 值=1.4 mg/mL)。它通过调节 PI3K/Akt 和 MAPK 信号通路防止癌细胞因细胞凋亡而死亡^[2]。
Myricetin 通过消除皮肤中的致病自由基而表现出抗光老化作用。Myricetin 能够抑制小鼠皮肤表皮 JB6 P+ 细胞中 UVB 诱导的 COX-2 表达。它抑制 UVB 诱导的激活蛋白 1 和 NF-κβ 的启动，以及 Fyn 激酶活性^[1]。
Myricetin 以剂量依赖性方式抑制 SKOV3 卵巢癌细胞的活力。它诱导 DNA DSBs 和 ER 应激，从而导致 SKOV3 细胞凋亡^[3]。
Myricetin 抑制人 Hsp70 超过 80%，IC₅₀ 值分别为 83、11 和 12 μM^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

用 Myricetin 处理原位胰腺肿瘤可使肿瘤消退并减少转移扩散^[2]。暴露于 150 μM Myricetin 可分别抑制由 ADP、花生四烯酸、胶原蛋白和 PAF 诱导的兔血小板聚集 14%、26%、5% 和 49%^[5]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

318.24

Formula

C₁₅H₁₀O₈

CAS 号

529-44-2

性状

固体

颜色

Light yellow to yellow

中文名称

杨梅素；杨梅酮

结构分类

初始来源

微生物

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

溶解性数据

细胞实验：

DMSO 中的溶解度 : ≥ 31 mg/mL (97.41 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

Ethanol 中的溶解度 : 28.57 mg/mL (89.78 mM; 超声助溶)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.1423 mL	15.7114 mL	31.4228 mL
5 mM	0.6285 mL	3.1423 mL	6.2846 mL
10 mM	0.3142 mL	1.5711 mL	3.1423 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C储存时，请在1年内使用， -20°C储存时，请在6个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.54 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.54 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 98.42%

选择批次：

Data Sheet (650 KB) SDS (393 KB)

COA (194 KB) RP-HPLC (208 KB) LCMS (94 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Semwal DK, et al. Myricetin: A Dietary Molecule with Diverse Biological Activities. Nutrients. 2016 Feb 16;8(2):90. [Content Brief]

[2]. Phillips PA, et al. Myricetin induces pancreatic cancer cell death via the induction of apoptosis and inhibition of thephosphatidylinositol 3-kinase (PI3K) signaling pathway. Cancer Lett. 2011 Sep 28;308(2):181-8. [Content Brief]

[3]. Xu Y, et al. Myricetin induces apoptosis via endoplasmic reticulum stress and DNA double-strand breaks in human ovarian cancer cells. Mol Med Rep. 2016 Mar;13(3):2094-100. [Content Brief]

[4]. Jinwal UK, et al. Chemical Manipulation of Hsp70 ATPase Activity Regulates Tau Stability. J Neurosci. 2009 Sep 30;29(39):12079-88. [Content Brief]

[5]. Tzeng SH, et al. Inhibition of platelet aggregation by some flavonoids. Thromb Res. 1991 Oct 1;64(1):91-100. [Content Brief]

Cell Assay ^[2]	Pancreatic cancer cells (MIA PaCa-2, Panc-1 or S2-013) or normal pancreatic ductal cells (PDCs) are treated with myricetin (12.5–200 μM). Cell viability is determined using the Dojindo Cell Counting Kit-8. Cells are seeded onto a 96-well plate at 1×10⁴ cells per well and allowed to adhere overnight. After treatment with myricetin at various concentrations for 24 hours, 10 μL of the tetrazolium substrate is added to each well of the plate. Plates are incubated at 37°C for 1 hour, after which the absorbance at 450 nm is measured^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[2]	Mice: Mice are given daily intraperitoneal injections of myricetin (30mg/kg in the MIA PaCa-2 model and 50mg/kg in the S2-013 model) or vehicle (DMSO) for 35 days (MIA PaCa-2 model) or 18 days (S2-013 model). Ultrasound measurements are performed at regular intervals to monitor tumor growth. At the end of the in vivo experiment, tumor size is measured using calipers and tumor volume is calculated^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Semwal DK, et al. Myricetin: A Dietary Molecule with Diverse Biological Activities. Nutrients. 2016 Feb 16;8(2):90. [Content Brief] [2]. Phillips PA, et al. Myricetin induces pancreatic cancer cell death via the induction of apoptosis and inhibition of thephosphatidylinositol 3-kinase (PI3K) signaling pathway. Cancer Lett. 2011 Sep 28;308(2):181-8. [Content Brief] [3]. Xu Y, et al. Myricetin induces apoptosis via endoplasmic reticulum stress and DNA double-strand breaks in human ovarian cancer cells. Mol Med Rep. 2016 Mar;13(3):2094-100. [Content Brief] [4]. Jinwal UK, et al. Chemical Manipulation of Hsp70 ATPase Activity Regulates Tau Stability. J Neurosci. 2009 Sep 30;29(39):12079-88. [Content Brief] [5]. Tzeng SH, et al. Inhibition of platelet aggregation by some flavonoids. Thromb Res. 1991 Oct 1;64(1):91-100. [Content Brief]

Myricetin 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

Ethanol / DMSO	1 mM	3.1423 mL	15.7114 mL	31.4228 mL	78.5571 mL
	5 mM	0.6285 mL	3.1423 mL	6.2846 mL	15.7114 mL
	10 mM	0.3142 mL	1.5711 mL	3.1423 mL	7.8557 mL
	15 mM	0.2095 mL	1.0474 mL	2.0949 mL	5.2371 mL
	20 mM	0.1571 mL	0.7856 mL	1.5711 mL	3.9279 mL
	25 mM	0.1257 mL	0.6285 mL	1.2569 mL	3.1423 mL
	30 mM	0.1047 mL	0.5237 mL	1.0474 mL	2.6186 mL
	40 mM	0.0786 mL	0.3928 mL	0.7856 mL	1.9639 mL
	50 mM	0.0628 mL	0.3142 mL	0.6285 mL	1.5711 mL
	60 mM	0.0524 mL	0.2619 mL	0.5237 mL	1.3093 mL
	80 mM	0.0393 mL	0.1964 mL	0.3928 mL	0.9820 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Myricetin529-44-2Cannabiscetin杨梅素杨梅酮PI3KApoptosisAutophagyEndogenous MetabolitePhosphoinositide 3-kinaseInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

Myricetin (Synonyms: 杨梅素; Cannabiscetin)

Customer Review

Other Forms of Myricetin:

MCE 顾客使用本产品发表的 13 篇科研文献

Myricetin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 PI3K 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Myricetin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Myricetin (Synonyms: 杨梅素; Cannabiscetin)

Customer Review

Other Forms of Myricetin:

Myricetin 相关抗体

MCE 顾客使用本产品发表的 13 篇科研文献

Myricetin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 PI3K 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

Myricetin 相关抗体:

摩尔计算器

稀释计算器

Myricetin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z